339 results about "Human patient" patented technology

Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, engaging an interventional device of a catheter system with clot material in a blood vessel and withdrawing the interventional device and the portion of the clot material through a guide catheter. In some embodiments, the catheter system can include an attachment / valve member coupled to a proximal portion of the guide catheter, and the method can include unsealing the attachment / valve member to facilitate withdrawing the interventional device through the attachment / valve member without significant retention of clot material within the attachment / valve member. The method can further include resealing and aspirating the guide catheter before advancing another interventional device to the clot material to again engage and remove clot material from the blood vessel.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in human patients for treating neurological and psychiatric conditions, such as agitation associated Alzheimer's disease and / or reducing relapse of agitation in Alzheimer's disease.

Systems and techniques are disclosed to adjust programming of an implantable electrical neurostimulation device for treating chronic pain of a human subject, through the use of a dynamic model adapted to identify pain treatment parameters for a human patient and determine a best device operational program to implement the pain treatment parameters to address the chronic pain condition. In an example, the system to adjust programming of the neurostimulation device performs operations that: obtain data related to a state of pain of the human subject; identify pain treatment parameters using a dynamic model adapted to evaluate the pain treatment parameters in the human subject over a time period, based on the data related to the state of pain; and select a neurostimulation program for the neurostimulation device, corresponding to at least a portion of the identified pain treatment parameters.

Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, engaging an interventional device of a catheter system with clot material in a blood vessel and withdrawing the interventional device and the portion of the clot material through a guide catheter. In some embodiments, the catheter system can include an attachment / valve member coupled to a proximal portion of the guide catheter, and the method can include unsealing the attachment / valve member to facilitate withdrawing the interventional device through the attachment / valve member without significant retention of clot material within the attachment / valve member. The method can further include resealing and aspirating the guide catheter before advancing another interventional device to the clot material to again engage and remove clot material from the blood vessel.

Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL- 13 in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL- 13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-13 antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL- 13). Also described herein are compositions and combinations comprising an antibody or an antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL- 13, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient are disclosed herein. A device in accordance with embodiments of the present technology can include, for example, a plurality of interconnected struts forming a unitary structure having a proximal portion and a distal portion. The struts can form a plurality of first cells in the proximal portion and a plurality of second cells, smaller than the first cells, in the distal portion. The device can be pulled against clot material within a blood vessel to engage, disrupt, and / or capture the clot material.

A system and method for distinguishing the type of seizures in a human patient, such as an epileptic seizure (ES), or a functional or dissociative seizure (FDS). The system and method use a diagnostic analytical platform that gets heart rate variability (HRV) analytical metrics from a ECG and uses an analytical diagnostic algorithm to determine if an ES or FDS has occurred in the patient. The diagnostic analytical platform can create a model for distinguishing that a predetermined type of seizure has occurred from the HRV analytical metrics.

Systems, methods, and computer-readable storage media are provided for determining and ascribing clinical conditions or diagnoses to patients and provide them to a caregiver, such as attending clinicians or other appropriate health services personnel. In particular, embodiments of the disclosure determine likely phenotypic findings that are salient to the decision-making context for a current human patient, based on anticipative sequence-mining and trajectory-mining. A sequential pattern mining and sequence itemset matching system is provided for determining likely, temporally-relevant concepts that are manifested in the information that is produced during the course of a patient's care. A clinician or caregiver may be provided the sequence itemset matching by generating a list or notice. In addition or alternatively, the results may be stored in an EHR associated with the patient.

The present disclosure relates to an apparatus for powering an implant for a human patient and a method for powering an implant for a human patient. Wherein said apparatus comprises an implantable energy source for providing energy to the implant, an energy provider connected to the implantable energy source and connected to an energy consuming part of the implant, the energy provider being configured to store energy to provide a burst of energy to the energy consuming part, wherein the energy provider is configured to be charged by the implantable energy source and to provide the energy consuming part with electrical power during startup of the energy consuming part.

Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.

Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient are disclosed herein. In one embodiment, a funnel catheter assembly includes an outer shaft and an inner shaft extending through and coaxial with the outer shaft. An expandable funnel can be coupled to a distal portion of the inner shaft. The funnel catheter assembly further includes a control assembly operably coupled to the proximal portion of the outer shaft and configured to move the outer shaft between a first position and a second position. In the first position, the outer shaft is positioned at least partially over the funnel to constrain the funnel in a compressed state. In the second position, the outer shaft is retracted proximally relative to the funnel such that the funnel can expand to an expanded state.

The disclosure relates to methods of treating multiple sclerosis using Ponesimod. In certain aspects, these include methods of avoiding worsening of fatigue-related symptoms in a human patient who has had no prior disease modifying treatment (DMT) for multiple sclerosis, who has a baseline expanded disability status scale (EDSS) score of ≤3.5, or who does not have Gd+ / T1 lesions at baseline.

Provided are dosages and methods for clinical treatment of human patients using an anti-OX40L antibody, or antigen binding fragment thereof.

Systems and methods for informing and evaluating neuromodulation therapy are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a guidewire having a proximal portion, a distal portion configured to be positioned at a target site in a blood vessel of a human patient, and a sensing element positioned along the distal portion. The sensing element can be a pressure sensing element, a flow sensing element, an impedance sensing element, and / or a temperature sensing element. The system can also include a controller configured to obtain one or more measurements related to a physiological parameter of the patient via the sensing element. Based on the measurements, the controller can determine the physiological parameter and compare the parameter to a predetermined threshold. Based on the comparison, the controller and / or an operator can evaluate the likelihood that the patient would benefit from neuromodulation therapy.

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL-4Rα in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL-4Rα biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-4Rα antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL-4). Also described herein are compositions and combinations comprising an antibody or antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL-4Rα, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

Methods of treating or ameliorating multiple sclerosis by the dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus or a pharmaceutically acceptable salt and / or a solvate, in particular a hydrate, thereof or a solvate, in particular a hydrate, of a pharmaceutically acceptable salt thereof, by administering to a human patient a therapeutically effective amount of the DHODH inhibitor, more specifically a daily dose of about 10 mg to about 45 mg.

A device immobilizes a shoulder joint and associated upper arm and forearm of a human patient in a selected relative position. The device comprises a platform including a planar base portion and a pair of opposed parallel side walls extending upwardly from the longitudinal edges of the base portion. The platform supportively receives and at least partially encloses the forearm of the patient. A mount defining a terminal slot is integral with at least one side wall. A belt is provided for securing around the waist of the patient. A belt clip attaches between the belt at a side of the body corresponding to the shoulder to be supported and the platform. The belt clip includes a lug projecting outwardly from the clip and corresponding in size and shape to the terminal slot for insertion into the slot, wherein the platform is suspended from the belt.

SOLUTION: The present invention provides a method for treating tumors in a human patient, the method including: (i) identifying a patient as having a LAG-3 positive tumor; and (ii) administering, to the patient, a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiment, the method further includes identifying the patient as having the LAG-3 positive PD-L1 positive tumors. In some embodiment, the LAG-3 inhibitor is an anti-LAG-3 antibody, and the PD-1 pathway inhibitor is an anti-PD-1 antibody.EFFECT: The method of the present invention can improve a response to a treatment with the PD-1 pathway inhibitor, the combination of the PD1 pathway inhibitor and the immune checkpoint inhibitor, or the combination of the LAG-3 inhibitor and the PD-1 pathway inhibitor.SELECTED DRAWING: None

Disclosed herein are systems and methods for endovascular treatment of clot material within a blood vessel of a human patient. In one embodiment, a system includes a coring element for coring and separating the clot material. The coring element may include a single structure having a first region, a second region, a third region, and a fourth region. The first region is adjacent to a proximal portion of the unitary structure and includes a first mouth configured to core and separate the clot material. The second region is distal to the first region, is substantially tubular, and includes a first plurality of interconnected struts. The third region is distal to the second region and includes a second mouth configured to core and separate a vascular thrombus. The fourth region is distal to the third region, is substantially tubular, and includes a second plurality of interconnected struts.

A method for assessing a lens capsule stability condition in an eye of a human patient includes simultaneously directing electromagnetic energy in a predetermined spectrum via an energy source onto a pupil of the eye after movement of the eye results in eye saccades occurring therein. The method further includes acquiring images of the eye indicative of the eye saccades using an image capture device and calculating a motion profile of the lens capsule using the images via an ECU. Additionally, the method includes extracting time-normalized lens capsule oscillation trajectories based on the motion profile via the ECU and then model fitting the lens capsule oscillation trajectories via the ECU, thereby assessing the lens capsule instability condition. Also disclosed herein is an automated system for performing an embodiment of the method, the automated system including an energy source, an image capture device, and an ECU.

The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K / mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K / mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K / mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.

The present invention relates to a pharmaceutical composition or formulation of an aprenomol citrate salt, which is a monodrug therapy or a combination therapy therapy with megranurite, for use in one or more methods of treating Niemann-Picker Disease Type C (NPC) in a human patient. The present invention also relates to aprenomol for use in a method of treating NPC in a human patient by dispersing or suspending a pharmaceutical composition comprising a formulation of aprenomol, in particular aprenomol citrate, in at least one liquid or at least one solid medium, and then administering to the patient. The present disclosure also relates to biomarkers and metabolites of aprenomol.

The present disclosure relates to systems and methods for intravascular treatment of intravascular clots in a human patient. A method according to an embodiment of the present technology may include, for example, positioning a distal portion of a catheter near an intravascular clot. The method may further include coupling a pressure source to the catheter via a conduit subsystem that includes a valve or other fluid control device, and activating the pressure source to charge a vacuum while the valve is closed. The valve may then be opened to apply the vacuum to the catheter, thereby sucking at least a portion of the clot into the catheter from the blood vessel.

The present invention relates to a method for the differential diagnosis of bipolar versus unipolar disorder in a human patient during a depressive phase from a biological sample of the patient, comprising determining the relative proportions of RNA editing variants of at least the A-to-I-edited RNA ZNF267 gene. The present invention also relates to a method for monitoring the treatment of a depressed patient exhibiting bipolar or unipolar disorder. Finally, the present invention provides a kit for the differential diagnosis of bipolar versus unipolar disorder in a patient during a depressive phase.

An acoustic respiratory monitoring system (105) detects, monitors, and / or tracks acoustic features of respiratory conditions for a human patient. Acoustic respiratory data is derived from breathing sound captured by a sensor array (410) comprising a plurality of acoustic sensor elements (412). A plurality of logical channels is determined based on the acoustic respiratory data. An adventitious feature is detected in the breathing sound using the plurality of logical channels, and an indication of an abnormal respiratory sound is provided via a user interface (800), in response to detecting the adventitious feature. The sensor array (410) may be integrated with a wearable article (560), such as a shirt, vest, or belt, for example.

Provided herein are methods of treating a patient, such as a human patient, having inflammation or an inflammatory disease or a disease in which inflammation is present, such as cardiovascular or vascular endothelium inflammation, such as pulmonary hypertension, restenosis, essential hypertension, atherosclerosis, stroke, sepsis, or a viral infection, such as a coronavirus infection, SARS-CoV-2. The methods comprise administering to the patient an amount of a compound as described herein effective to treat the patient. NCOA7-activating compounds and compositions also are provided. Also provided is a gene editing method of reducing inflammation or an inflammatory condition in a patient having a C at SNP rs 11154337, comprising editing the C to a G.

In an illustrative embodiment, systems and methods for treating kidney disease in a human patient are disclosed. A method includes advancing a collapsible array of RF electrodes through a urinary tract of the patient in collapsed form and into a position in or near a renal pelvis. The effector is deployed to an expanded form to engage at least a portion of an interior wall of the renal pelvis. RF energy delivered through the array of electrodes target afferent nerves proximate the interior wall of the renal pelvis to inhibit or destroy their function. eGFR of the patient can be raised after treatment according to the method.

A method to treat a human patient including: advancing a catheter through a natural airway of the patient and positioning a distal portion of the catheter in the natural airway of a lung of the patient to a target region in the lung, injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight / volume from the distal portion of the catheter into the target region; delivering energy from the distal portion into the conductive hypertonic saline solution in the target region, wherein the energy heats the liquid in the portion of the airway, and ablating the target region with the heated liquid.

The present disclosure relates to administering in a human patient a combination of: 1) about 100 to 110 mg, about 104 to 106 mg, or about 105 mg or less of bupropion hydrochloride or a molar equivalent amount of bupropion in a free base form or another salt form; and 2) a free base form or another salt form of dextromethorphan hydrobromide or a molar equivalent amount of dextromethorphan or a molar equivalent amount of dextromethorphan or another salt form of about 40-50 mg, about 44-46 mg, or about 45 mg or less for use in the treatment of neurological and psychiatric conditions, such as agitation associated with Alzheimer's disease, and / or reducing recurrence of agitation in Alzheimer's disease.